134.75
전일 마감가:
$134.75
열려 있는:
$134.79
하루 거래량:
948.28K
Relative Volume:
0.36
시가총액:
$10.20B
수익:
-
순이익/손실:
$-274.62M
주가수익비율:
-31.14
EPS:
-4.3278
순현금흐름:
$-235.37M
1주 성능:
+0.15%
1개월 성능:
+0.41%
6개월 성능:
+97.03%
1년 성능:
+270.70%
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
APGE
Apogee Therapeutics Inc
|
134.75 | 10.20B | 0 | -274.62M | -235.37M | -4.3278 |
|
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Hold |
| 2026-01-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | 개시 | Wolfe Research | Peer Perform |
| 2025-12-17 | 개시 | Stephens | Overweight |
| 2025-12-10 | 개시 | Deutsche Bank | Buy |
| 2025-11-03 | 개시 | Craig Hallum | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-07 | 재확인 | BTIG Research | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
Apogee Therapeutics Market Sentiment - Benzinga España
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighShould You Buy? - MarketBeat
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal - TradingView
What Will Apogee Therapeutics (NASDAQ:APGE) Say on Trials? - Kalkine Media
Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO Dambkowski sells $737k in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $737k in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liquidity Mapping Around (APGE) Price Events - news.stocktradersdaily.com
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Handelsbanken Fonder AB Has $11.46 Million Stake in Apogee Therapeutics Inc. $APGE - MarketBeat
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Truist Financial Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Raises Target Price to $135 - Moomoo
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History - Yahoo Finance
Apogee Therapeutics Director Vote: My Take On The 8-K Liga Mx (YjhKcvC1lD) - Mshale
Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research - MarketBeat
APGE Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
BTIG Downgrades Apogee Therapeutics to Neutral From Buy - marketscreener.com
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal By Investing.com - Investing.com South Africa
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal - Investing.com Nigeria
APOGEE THERAPEUTICS, INC. : BTIG CUTS TO NEUTRAL FROM BUY - Bitget
Apogee Therapeutics Directors Execute Stock Options, Increasing Holdings - Kalkine Media
Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options - Stock Titan
Apogee Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com
Apogee Therapeutics,Q2 2026 Net Loss $85.9 - Moomoo
My Takeaway On Apogee Therapeutics' Massive Cash Raise Humberto Cruz (GVA0ZiS739) - Mshale
Apogee Therapeutics, Inc. (APGE): An Insightful Stock Analysis on Growth Potential and Market Position - DirectorsTalk Interviews
APGE SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus
Apogee Therapeutics Reports Q2 2026 Results and Announces Merger Agreement with AbbVie Subsidiary - Kalkine Media
Apogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary - TradingView
Apogee Therapeutics (APGE) details Q2 2026 losses, AbbVie merger plan and $100M BXLS deal - Stock Titan
Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS - MarketBeat
Apogee Therapeutics Q2 Loss Widens - marketscreener.com
Earnings Flash (APGE) Apogee Therapeutics Posts Q2 Net Loss $85.9M, vs. FactSet Est of $78.7M Loss - marketscreener.com
Apogee reports $85.9 million Q2 loss as AbbVie deal advances - Quiver Quantitative
Apogee Therapeutics reports Q2 2026 results; cash and marketable securities $1.3B, net loss $85.9M - TradingView
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates - The Manila Times
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results - Quiver Quantitative
Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75 - Stock Titan
Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of America Corp DE - MarketBeat
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares By Investing.com - Investing.com India
Apogee Therapeutics CMO Carl Dambkowski disposes of USD 737,935 in common shares - Bitget
Apogee Therapeutics (APGE) CMO trades stock under 10b5-1 plan - Stock Titan
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Sei Investments Co. Grows Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics stock hits all-time high at 134.47 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock hits all-time high at 134.47 USD - Investing.com
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):